Literature DB >> 20625909

Neonatal staphylococcal scalded skin syndrome: clinical and outbreak containment review.

Orla Neylon1, Nuala H O'Connell, Barbara Slevin, James Powell, Regina Monahan, Liz Boyle, Dominic Whyte, Mai Mannix, Fiona McElligott, Angela M Kearns, Roy K Philip.   

Abstract

Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliating skin condition predominated by desquamation and blistering. Neonatal outbreaks have already been reported; however, our outbreak highlights the potential for SSSS following neonatal health promotion measures such as intra-muscular vitamin K administration and metabolic screening (heel prick) as well as effective case containment measures and the value of staff screening. Between February and June 2007, five confirmed cases of neonatal SSSS were identified in full-term neonates born in an Irish regional maternity hospital. All infants were treated successfully. Analysis of contact and environmental screening was undertaken, including family members and healthcare workers. Molecular typing on isolates was carried out. An outbreak control team (OCT) was assembled and took successful prospective steps to prevent further cases. All five Staphylococcus aureus isolates tested positive for exfoliative toxin A, of which two distinct strains were identified on pulsed-field gel electrophoresis analysis. Two cases followed staphylococcal inoculation during preventive measures such as intra-muscular vitamin K administration and metabolic screening (heel prick). None of the neonatal isolates were methicillin resistant. Of 259 hospital staff (70% of staff) screened, 30% were colonised with S. aureus, and 6% were positive for MRSA carriage. This is the first reported outbreak of neonatal SSSS in Ireland. Effective case containment measures and clinical value of OCT is demonstrated. Results of staff screening underlines the need for vigilance and compliance in hand disinfection strategies in maternity hospitals especially during neonatal screening and preventive procedures.

Entities:  

Mesh:

Year:  2010        PMID: 20625909     DOI: 10.1007/s00431-010-1252-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  23 in total

1.  Familial outbreak of staphylococcal scalded skin syndrome.

Authors:  S Ladhani; T Newson
Journal:  Pediatr Infect Dis J       Date:  2000-06       Impact factor: 2.129

2.  Neonatal staphylococcal skin infections.

Authors:  Howard Faden
Journal:  Pediatr Infect Dis J       Date:  2003-04       Impact factor: 2.129

Review 3.  Experience with severe extensive blistering skin disease in a paediatric burns unit.

Authors:  J E Greenwood; K W Dunn; P J Davenport
Journal:  Burns       Date:  2000-02       Impact factor: 2.744

Review 4.  Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome.

Authors:  John R Stanley; Masayuki Amagai
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

5.  Nasal, axillary, and perineal carriage of Staphylococcus aureus among women: identification of strains producing epidermolytic toxin.

Authors:  S J Dancer; W C Noble
Journal:  J Clin Pathol       Date:  1991-08       Impact factor: 3.411

Review 6.  Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome.

Authors:  S Ladhani; C L Joannou; D P Lochrie; R W Evans; S M Poston
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

7.  Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease.

Authors:  A Holmes; M Ganner; S McGuane; T L Pitt; B D Cookson; A M Kearns
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

Review 8.  Treatment of staphylococcal scalded skin syndrome.

Authors:  Girish K Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2004-08       Impact factor: 5.091

9.  Neonatal staphylococcal scalded skin syndrome: massive outbreak due to an unusual phage type.

Authors:  J P Curran; F L Al-Salihi
Journal:  Pediatrics       Date:  1980-08       Impact factor: 7.124

10.  Importance of exfoliatin toxin A production by Staphylococcus aureus strains isolated from clustered epidemics of neonatal pustulosis.

Authors:  M H Kaplan; H Chmel; H C Hsieh; A Stephens; V Brinsko
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

View more
  5 in total

1.  Rapid detection of live methicillin-resistant Staphylococcus aureus by using an integrated microfluidic system capable of ethidium monoazide pre-treatment and molecular diagnosis.

Authors:  Yu-Hsin Liu; Chih-Hung Wang; Jiunn-Jong Wu; Gwo-Bin Lee
Journal:  Biomicrofluidics       Date:  2012-09-10       Impact factor: 2.800

2.  Is heel prick as safe as we think?

Authors:  Roberta Onesimo; Maria Fioretti; Stefania Pili; Serena Monaco; Costantino Romagnoli; Carlo Fundarò
Journal:  BMJ Case Rep       Date:  2011-10-16

3.  Antibiotic sensitivity and resistance patterns in pediatric staphylococcal scalded skin syndrome.

Authors:  Inbal Braunstein; Karolyn A Wanat; Katrina Abuabara; Karin L McGowan; Albert C Yan; James R Treat
Journal:  Pediatr Dermatol       Date:  2013-08-23       Impact factor: 1.588

4.  Rapid containment of nosocomial transmission of a rare community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) clone, responsible for the Staphylococcal Scalded Skin Syndrome (SSSS).

Authors:  Onofrio Lamanna; Dafne Bongiorno; Lisa Bertoncello; Stefano Grandesso; Sandra Mazzucato; Giovanni Battista Pozzan; Mario Cutrone; Michela Chirico; Flavia Baesso; Pierluigi Brugnaro; Viviana Cafiso; Stefania Stefani; Floriana Campanile
Journal:  Ital J Pediatr       Date:  2017-01-06       Impact factor: 2.638

5.  An outbreak of skin infections in neonates due to a Staphylococcus aureus strain producing the exfoliative toxin A.

Authors:  Fernanda Pimentel de Araujo; Marco Tinelli; Antonio Battisti; Angela Ercoli; Adriano Anesi; Annalisa Pantosti; Monica Monaco
Journal:  Infection       Date:  2017-11-06       Impact factor: 7.455

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.